1521 Stock Overview
Frontage Holdings Corporation, a contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies, as well as bioequivalence studies.
No risks detected for 1521 from our risk checks.
Frontage Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$2.51|
|52 Week High||HK$6.15|
|52 Week Low||HK$1.98|
|1 Month Change||-23.48%|
|3 Month Change||-1.18%|
|1 Year Change||-58.03%|
|3 Year Change||-21.56%|
|5 Year Change||n/a|
|Change since IPO||-25.07%|
Recent News & Updates
Is It Too Late To Consider Buying Frontage Holdings Corporation (HKG:1521)?
While Frontage Holdings Corporation ( HKG:1521 ) might not be the most widely known stock at the moment, it received a...
|1521||HK Life Sciences||HK Market|
Return vs Industry: 1521 underperformed the Hong Kong Life Sciences industry which returned -38.9% over the past year.
Return vs Market: 1521 underperformed the Hong Kong Market which returned -22.7% over the past year.
|1521 Average Weekly Movement||7.1%|
|Life Sciences Industry Average Movement||7.6%|
|Market Average Movement||6.6%|
|10% most volatile stocks in HK Market||12.8%|
|10% least volatile stocks in HK Market||3.2%|
Stable Share Price: 1521 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 1521's weekly volatility (7%) has been stable over the past year.
About the Company
Frontage Holdings Corporation, a contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies, as well as bioequivalence studies. It offers laboratory testing services, such as method development and validation, and sample analysis and central laboratory services; chemistry, manufacturing, and control services, including assistance in drug product development and analysis, and delivery and supply of clinical trial materials; and drug metabolism and pharmacokinetic services that include study designs, execution of studies, and interpretation of the data through structural optimization in early discovery, pharmacokinetic studies in rodents, non- GLP bioanalytical studies, etc. The company also provides safety and toxicology services comprising in-vitro and in-vivo studies; bioequivalence services, which consist of designing, coordinating, and reporting of bioequivalence studies; chemistry services comprising contract research and custom synthesis services; and clinical services, such as early stage clinical, BE/BA, biometric, and data management services. It operates in the United States, the People’s Republic of China, Europe, India, Japan, South Korea, and Australia.
Frontage Holdings Fundamentals Summary
|1521 fundamental statistics|
Is 1521 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|1521 income statement (TTM)|
|Cost of Revenue||US$117.74m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||0.0089|
|Net Profit Margin||9.99%|
How did 1521 perform over the long term?See historical performance and comparison
Is 1521 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1521?
Other financial metrics that can be useful for relative valuation.
|What is 1521's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 1521's PE Ratio compare to its peers?
|1521 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
6118 Austar Lifesciences
1873 Viva Biotech Holdings
8225 China Health Group
2269 WuXi Biologics (Cayman)
1521 Frontage Holdings
Price-To-Earnings vs Peers: 1521 is expensive based on its Price-To-Earnings Ratio (35.8x) compared to the peer average (26.5x).
Price to Earnings Ratio vs Industry
How does 1521's PE Ratio compare vs other companies in the Asian Life Sciences Industry?
Price-To-Earnings vs Industry: 1521 is expensive based on its Price-To-Earnings Ratio (35.8x) compared to the Hong Kong Life Sciences industry average (12.1x)
Price to Earnings Ratio vs Fair Ratio
What is 1521's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||35.8x|
|Fair PE Ratio||16.2x|
Price-To-Earnings vs Fair Ratio: 1521 is expensive based on its Price-To-Earnings Ratio (35.8x) compared to the estimated Fair Price-To-Earnings Ratio (16.2x).
Share Price vs Fair Value
What is the Fair Price of 1521 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 1521 (HK$2.51) is trading below our estimate of fair value (HK$8.45)
Significantly Below Fair Value: 1521 is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Frontage Holdings forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1521's forecast earnings growth (27.9% per year) is above the savings rate (1.6%).
Earnings vs Market: 1521's earnings (27.9% per year) are forecast to grow faster than the Hong Kong market (16.7% per year).
High Growth Earnings: 1521's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 1521's revenue (18.2% per year) is forecast to grow faster than the Hong Kong market (10% per year).
High Growth Revenue: 1521's revenue (18.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1521's Return on Equity is forecast to be low in 3 years time (11.3%).
Discover growth companies
How has Frontage Holdings performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1521 has high quality earnings.
Growing Profit Margin: 1521's current net profit margins (10%) are lower than last year (13.6%).
Past Earnings Growth Analysis
Earnings Trend: 1521's earnings have grown by 15.2% per year over the past 5 years.
Accelerating Growth: 1521's earnings growth over the past year (7.5%) is below its 5-year average (15.2% per year).
Earnings vs Industry: 1521 earnings growth over the past year (7.5%) underperformed the Life Sciences industry 34.5%.
Return on Equity
High ROE: 1521's Return on Equity (5.9%) is considered low.
Discover strong past performing companies
How is Frontage Holdings's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 1521's short term assets ($211.1M) exceed its short term liabilities ($73.0M).
Long Term Liabilities: 1521's short term assets ($211.1M) exceed its long term liabilities ($79.8M).
Debt to Equity History and Analysis
Debt Level: 1521 has more cash than its total debt.
Reducing Debt: 1521's debt to equity ratio has reduced from 19.4% to 0% over the past 5 years.
Debt Coverage: 1521's debt is well covered by operating cash flow (404990.9%).
Interest Coverage: 1521's interest payments on its debt are well covered by EBIT (36.5x coverage).
Discover healthy companies
What is Frontage Holdings's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 1521's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 1521's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1521's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1521's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 1521 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Frontage Holdings has no CEO, or we have no data on them.
Experienced Management: 1521's management team is considered experienced (2.4 years average tenure).
Experienced Board: 1521's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Frontage Holdings Corporation's employee growth, exchange listings and data sources
- Name: Frontage Holdings Corporation
- Ticker: 1521
- Exchange: SEHK
- Founded: 2018
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$5.487b
- Shares outstanding: 2.06b
- Website: https://www.frontagelab.com
Number of Employees
- Frontage Holdings Corporation
- 700 Pennsylvania Drive
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/10 00:00|
|End of Day Share Price||2022/08/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.